Literature DB >> 17170077

Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting.

Ilse Houtenbos1, Theresia M Westers, Annemiek Dijkhuis, Tanja D de Gruijl, Gert J Ossenkoppele, Arjan A van de Loosdrecht.   

Abstract

PURPOSE: Acute myelogenous leukemia (AML) blasts are able to differentiate into leukemia-derived dendritic cells (AML-DC), thereby enabling efficient presentation of known and unknown leukemic antigens. Advances in culture techniques and AML-DC characterization justify clinical application. However, additional measures are likely needed to potentiate vaccines and overcome the intrinsic tolerant state of the patients' immune system. Engagement of the costimulatory molecule 4-1BB can break immunologic tolerance and increase CTL responses. In this study, we examined the role of the 4-1BB ligand (4-1BBL) on T-cell responses induced by AML-DC. EXPERIMENTAL
DESIGN: In allogeneic and autologous cocultures of T cells and AML-DC, the effect of the addition of 4-1BBL on T-cell proliferation, T-cell subpopulations, and T-cell function was determined.
RESULTS: Addition of 4-1BBL to cocultures of AML-DC and T cells induced a preferential increase in the proliferation of CD8(+) T cells. Increased differentiation into effector and central memory populations was observed in both CD4(+) and CD8(+) T cells in the presence of 4-1BBL. AML-DC induce a T helper 1 response, characterized by high IFN-gamma production, which is significantly increased by targeting 4-1BB. T cells primed in the presence of 4-1BBL show specificity for the leukemia-associated antigen Wilms' tumor 1, whereas cytotoxicity assays with leukemic blast targets showed the cytolytic potential of T cells primed in the presence of 4-1BBL.
CONCLUSION: We conclude that 4-1BBL is an effective adjuvant to enhance T-cell responses elicited by AML-DC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17170077     DOI: 10.1158/1078-0432.CCR-06-1430

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

Review 1.  The characterization and role of leukemia cell-derived dendritic cells in immunotherapy for leukemic diseases.

Authors:  Changjin Yuan; Guanhua Song; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2012-05

2.  Therapeutic vaccination with 4-1BB co-stimulation eradicates mouse acute myeloid leukemia.

Authors:  Daniel Kerage; Megan S F Soon; Brianna L Doff; Takumi Kobayashi; Michael D Nissen; Pui Yeng Lam; Graham R Leggatt; Stephen R Mattarollo
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

3.  Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies.

Authors:  Wei Lin; Caroline J Voskens; Xiaoyu Zhang; Daniel G Schindler; Aaron Wood; Erin Burch; Yadong Wei; Lieping Chen; Guoliang Tian; Koji Tamada; Lai-Xi Wang; Dan H Schulze; Dean Mann; Scott E Strome
Journal:  Blood       Date:  2008-06-02       Impact factor: 22.113

4.  Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene.

Authors:  Monica Casucci; Serena Kimi Perna; Laura Falcone; Barbara Camisa; Zulma Magnani; Massimo Bernardi; Alessandro Crotta; Cristina Tresoldi; Katharina Fleischhauer; Maurilio Ponzoni; Silvia Gregori; Federico Caligaris Cappio; Fabio Ciceri; Claudio Bordignon; Alessandro Cignetti; Attilio Bondanza; Chiara Bonini
Journal:  Mol Ther       Date:  2012-11-13       Impact factor: 11.454

Review 5.  Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2011-04-26

6.  2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.

Authors:  Yingxi Xu; Qian Liu; Mengjun Zhong; Zhenzhen Wang; Zhaoqi Chen; Yu Zhang; Haiyan Xing; Zheng Tian; Kejing Tang; Xiaolong Liao; Qing Rao; Min Wang; Jianxiang Wang
Journal:  J Hematol Oncol       Date:  2019-05-16       Impact factor: 17.388

7.  The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell responses.

Authors:  Isabel Barao
Journal:  Front Immunol       Date:  2013-01-04       Impact factor: 7.561

Review 8.  Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.

Authors:  Anna Aureli; Beatrice Marziani; Tommaso Sconocchia; Maria Ilaria Del Principe; Elisa Buzzatti; Gianmario Pasqualone; Adriano Venditti; Giuseppe Sconocchia
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.